Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04726527 · ClinicalTrials.gov registry record
Clinical Evaluation of Florbetapir in Primary Progressive Aphasia
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 48
- Enrollment target
NCT04726527: Completed study, sponsored by University of Chicago.
NCT04726527 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04726527 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
Study Summary
The purpose of this research is to better understand how dementia affects activity in different parts of the brain.
Primary Outcome
The study will provide standardized conditions for florbetapir F 18 use, amyloid binding as measured by PET imaging, and long-term outcome in cognitively normal volunteers, patients with Alzheimer's Disease, patients with Mild Cognitive Impairment, and patients with other neurodegenerative diseases. It will also facilitate evaluation of subject's amyloid burden in companion studies such as longitudinal studies of aging, studies of progressive cognitive impairment, and studies of imaging and bloo
Interventions
- DEVICE Positron Emission Tomography
- DRUG Florbetapir F 18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2012-03-15 |
| Est. Completion | 2017-02-28 |
What the finished NCT04726527 record still lists
NCT04726527 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 48 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Positron Emission Tomography is the first listed.
NCT04726527 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04726527 about?
NCT04726527 is a clinical study titled "Clinical Evaluation of Florbetapir in Primary Progressive Aphasia". The purpose of this research is to better understand how dementia affects activity in different parts of the brain.
What is the current status of trial NCT04726527?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2012-03-15. Estimated completion is 2017-02-28.
What interventions are being tested in trial NCT04726527?
The interventions under investigation include: Positron Emission Tomography (DEVICE), Florbetapir F 18 (DRUG).
Who is sponsoring clinical trial NCT04726527?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI